COVID-19

COVID-19 Vaccines

Innovative vaccine platforms such as DNA, mRNA, virus-like particles, viral vector, recombinant protein, and live attenuated and inactivated virus approaches have developed COVID-19 vaccines.

On August 23, 2021, the U.S. Food and Drug Administration (FDA) Authorized the Pfizer-BioNTech mRNA Comirnaty vaccine and Approved the SpikeVax from Moderna, Inc., and the Jcovden - Janssen COVID-19 vaccine was Authorized for use in the USA as of June 2022. In addition, on July 13, 2022, the FDA authorized Novavax's protein-based COVID-19 vaccine.

This U.S. CDC Morbidity and Mortality Weekly Report highlights COVID-19 vaccine safety and effectiveness information.

The European Medicines Agency (EMA) has Authorized (7) COVID-19 vaccines as of December 2022.

Furthermore, the World Health Organization (WHO) has Listed various COVID-19 vaccines. In addition, on December 2, 2022, the WHO published a standard analytic report produced by the COVID-19 Vaccine Delivery Partnership of key COVID-19 vaccine implementation data, including 1) daily vaccination rate, 2) population coverage, 3) supply secured & received, and 4) product utilization data, for across COVAX AMC portfolio and CoVDP's Countries for Concerted Support.

And GAVI recently reported over (120) COVID-19 vaccine candidates underwent clinical trials.

Additional vaccine news is published at PrecisionVaccinations.com/vaccines.

COVID-19 Antivirals

The U.S. FDA has Approved and Authorized various antivirals (oral and IV) to treat COVID-19 infections.

SARS-CoV-2 9 Monoclonal Antibody

The U.S. FDA has Authorized various monoclonal antibody therapies during the COVID-19 pandemic.